VanEck Semiconductor ETF (SMH) NPORT-P VanEck Biotech ETF (Dec 2024 report)

VANECK

BIOTECH

ETF

SCHEDULE

OF

INVESTMENTS

December

31,

2024

(unaudited)

1

FootnoteRuleAboveBlank

Footnotes:

Number

of

Shares

Value

COMMON

STOCKS

:

100.0%

China

:

1.8%

BeiGene

Ltd.

(ADR) *

38,215

$

7,058,693

Underline

Germany

:

2.6%

BioNTech

SE

(ADR) *

90,869

10,354,522

Underline

Ireland

:

3.7%

ICON

Plc

(USD) *

68,780

14,423,854

Underline

United

States

:

91.9%

Alnylam

Pharmaceuticals,

Inc. *

63,207

14,873,239

Amgen,

Inc.

234,981

61,245,448

Argenx

SE

(ADR) *

34,260

21,069,900

Biogen,

Inc. *

88,549

13,540,913

BioMarin

Pharmaceutical,

Inc. *

84,057

5,525,067

Bio-Techne

Corp.

115,242

8,300,881

Charles

River

Laboratories

International,

Inc. *

39,093

7,216,568

Cytokinetics,

Inc. *

54,364

2,557,283

Exact

Sciences

Corp. *

†

99,768

5,605,964

Number

of

Shares

Value

United

States

(continued)

Gilead

Sciences,

Inc.

501,791

$

46,350,435

Illumina,

Inc. *

†

122,802

16,410,031

Incyte

Corp. *

92,521

6,390,425

Insmed,

Inc. *

119,234

8,231,915

IQVIA

Holdings,

Inc. *

92,910

18,257,744

Moderna,

Inc. *

248,928

10,350,426

Natera,

Inc. *

111,280

17,615,624

Neurocrine

Biosciences,

Inc. *

76,409

10,429,829

QIAGEN

NV

166,783

7,426,847

Regeneron

Pharmaceuticals,

Inc. *

36,676

26,125,415

Repligen

Corp. *

35,693

5,137,650

Sarepta

Therapeutics,

Inc. *

74,896

9,106,605

Vertex

Pharmaceuticals,

Inc. *

102,210

41,159,967

362,928,176

Total

Common

Stocks

(Cost:

$418,218,900)

394,765,245

Total

Investments:

100.0%

(Cost:

$418,218,900)

394,765,245

Other

assets

less

liabilities:

0.0%

129,849

NET

ASSETS:

100.0%

$

394,895,094

Definitions:

ADR

American

Depositary

Receipt

USD

United

States

Dollar

*

Non-income

producing

†

Security

fully

or

partially

on

loan.

Total

market

value

of

securities

on

loan

is

$19,648,252.